Company news
AtaiBeckley Inc. news in 2022
AtaiBeckley Inc.'s news releases, calls and decks from 2022, newest first.
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
December 22, 2022
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
December 18, 2022
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
December 15, 2022
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
November 28, 2022
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
November 16, 2022
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
November 9, 2022
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
October 31, 2022
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
October 31, 2022
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
October 24, 2022
atai Life Sciences Announces R&D Day Agenda
October 19, 2022
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
October 17, 2022
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
October 11, 2022
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
October 4, 2022
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
October 3, 2022
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
September 26, 2022
atai Life Sciences to Participate in September Investor Events
September 5, 2022
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
August 14, 2022
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
August 14, 2022
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
July 31, 2022
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
June 29, 2022
Stephen Bardin to Join atai Life Sciences as CFO Designate
June 16, 2022
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
June 15, 2022
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
May 15, 2022
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
May 4, 2022
atai Life Sciences to Announce First-Quarter 2022 Financial Results
May 3, 2022
atai Life Sciences to Participate in Upcoming April Investor Conference
April 18, 2022
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
March 29, 2022
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
March 22, 2022
atai Life Sciences to Participate in Upcoming March Investor Conferences
March 20, 2022
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
February 15, 2022
atai Life Sciences to Participate in Upcoming February Investor Conference
February 14, 2022
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
January 26, 2022
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
January 11, 2022
atai Life Sciences to Participate in Upcoming January Investor Conference
January 9, 2022